NCT05858320CompletedPhase 3
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients (SmartHF)
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a computable medication optimization algorithm. The algorithm provides a medication quality score and outputs medication optimization recommendations written in a patient -friendly manner.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 225 (actual)
- First submitted
- 1 May 2023
- Start date
- 21 Jul 2023
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- University of Michigan
- Diseases
- Heart failure
- NCT number
- NCT05858320
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 225
- From 21 Jul 2023 to the primary completion date, 1 Dec 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with chronic inotropic therapy
Other illness
- Actively treated cancer, except non-melanoma skin cancer
Other
- End-stage HF (hospice candidate)
- Implanted ventricular assist device
- Patient's provider for HFrEF care is considered an advanced HF specialist
- Currently pregnant or intends to become pregnant during the study period
- Dialysis
Who the study is looking for
- Age 18 years and older at screening
- Diagnosis of heart failure with a left ventricular ejection fraction (LVEF) \</= 40% (HFrEF)
- Have a general medicine provider or general cardiology provider for HFrEF
- Have internet access and access to their health system's patient portal
- Fluent in spoken and written English
- At least two of the following: systolic blood pressure ≥ 110mmg, potassium ≤ 5.5, serum creatinine ≤ 2.5, heart rate ≥ 70
- At least two eligible heart failure therapies (guideline-recommended BB, RASI, MRA, or SGLT2i) not yet initiated or below 50% of the target dose
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| Emory University, Grady Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Henry Ford Hospital and Health System Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| Washington University, Barns Jewish Hospital Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
| Trinity Healthcare St. Joseph Mercy Ann Arbor Coordinator of this site? Confirm its status | Ypsilanti | United States | Unknown status |
Related publications
- The impact of an adaptive patient-centered web application on medication optimization in patients with HFrEF: Rationale and design of the SmartHF trial.Am Heart J Plus · 2026 · PMID 42898174
This page is information, not medical advice. Discuss any trial with your doctor.